PT -期刊文章盟Jiwon哦-丹尼尔·哈里森盟盟-克雷格·琼斯AU -小君华盟-艾米丽木非盟-彼得·卡拉布雷西AU - Peter Van Zijl AU -丹尼尔帝国TI -皮质病变的方法分析在多发性硬化症7-Tesla MRI (P03.064) DP - 2012年4月24日TA -神经病学PG - P03.064 P03.064 VI - 78 IP - 1补充4099 - //www.ez-admanager.com/content/78/1_Supplement/P03.064.short 4100 - http://n.neurol首页ogy.org/content/78/1_Supplement/P03.064.full所以Neurology2012 4月24日;78 AB -目的:创建一个标准方法分析皮层病变如7-Tesla (7 t) MRI在多发性硬化症(MS)。背景皮质病变一直在解剖研究MS,但是直到最近才确定这些病变MRI。7 t MRI可能允许可视化这些病变,但不同协议描述和没有标准化的方法进行分析。在这项研究中,我们旨在确定这些病变的正确序列进行识别,并创建一个图像分析技术允许可靠的、可再生的皮质损伤分析。设计/方法:以下7点全脑序列得到t 36女士主题:3 d磁化准备快速梯度回波(MPRAGE)(女士女士TR: 5.1, 2.2, 0.5毫米各向同性),3 d T2 *三gradient-echo (T2 * gre) (TR: 37女士,TE: 15和30毫秒,女士0.5毫米各向同性),3 d magnetization-prepared液体衰减反转恢复(MPFLAIR) (TR: 8000 MS, TE: 292 MS, TI: 2175毫秒,1.0毫米各向同性)。图像使用MIPAV软件包进行了分析。综述了图像在三个正交平面对应的片。感兴趣的区域被吸引在边界leukocortical,皮层,单纯皮质病变。病变类型、计数和体积都被记录下来。Results: Lesions were best identified as hypointensities on MPRAGE. Compared to T2*-GRE and MPFLAIR, the resolution of this sequence and distinct grey-white border allowed differentiation of cortical lesion subtypes and avoided misidentification of juxtacortical lesions as leukocortical or intracortical. A spatial image filter was required to reduce heterogeneity across differing regions of cortex. Dielectric padding was necessary to reduce image artifact in the temporal lobes.Conclusions: 7T MPRAGE allows classification of lesion subtype and avoids misidentification of juxtacortical lesions as within cortex. The image analysis methodology proposed may be applicable to future studies of cortical pathology in MS.Supported by: In part, by grants from Bayer Schering Pharma and NIH Supplemental Grant 5P41 RR15241-09S1 (van Zijl).Disclosure: Dr. Harrison has nothing to disclose. Dr. Oh has nothing to disclose. Dr. Jones has nothing to disclose. Dr. Hua has nothing to disclose. Dr. Wood has nothing to disclose. Dr. Calabresi has received personal compensation for activities with Teva, Biogen Idec, Novartis, Genzyme, Johnson & Johnson, and Vertex. Dr. Calabresi has received research support from Biogen Idec, Teva, EMD Serono, Vertex, Genentech, Abbott, and Bayer. Dr. van Zijl has received personal compensation for activities with Philips Medical Systems and Kennedy Krieger Institute as a speaker or consultant. Dr. van Zijl has received research support from Philips Medical Systems. Dr. Reich has nothing to disclose.Tuesday, April 24 2012, 14:00 pm-18:30 pm